Skip to content
Veracyte® Investor Relations
Veracyte is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment.
The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California.

Veracyte® Investor Relations

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 11, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced the appointment of Eliav Barr , M.D., to its board of directors, effective immediately. “We are thrilled to welcome Eliav Barr to our board,” said Marc Stapley , Veracyte’s chief executive
Toggle Summary Veracyte Announces Second Quarter 2022 Financial Results
Grew Total Revenue to $72.9 million , an Increase of 32% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 2, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2022 .


There are currently no events to display.


Title Documents

Corporate Presentation August 2022